|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fondaparinux#Adult Indications and Dosage]] |
| {{Fondaparinux}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
|
| |
|
| ==Dosage And Administration==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| Do not mix other medications or solutions with ARIXTRA. Administer ARIXTRA only subcutaneously.
| | [[Category: Anticoagulants]] |
| | |
| ===Deep Vein Thrombosis Prophylaxis===
| |
| Following the following procedures:
| |
| *Hip Fracture Surgery
| |
| | |
| *Hip Replacement Surgery
| |
| | |
| *Knee Replacement Surgery
| |
| In patients undergoing hip fracture, hip replacement, or knee replacement surgery, the recommended dose of ARIXTRA is 2.5 mg administered by subcutaneous injection once daily after [[hemostasis ]]has been established. Administer the initial dose no earlier than 6 to 8 hours after surgery. Administration of ARIXTRA earlier than 6 hours after surgery increases the risk of major bleeding. The usual duration of therapy is 5 to 9 days; up to 11 days of therapy was administered in clinical trials.
| |
| | |
| In patients undergoing hip fracture surgery, an extended prophylaxis course of up to 24 additional days is recommended. In patients undergoing hip fracture surgery, a total of 32 days (peri-operative and extended prophylaxis) was administered in clinical trials. [See [[Fondaparinux warnings and precautions |Warnings and Precautions (5.6)]], [[Fondaparinux adverse reactions|Adverse Reactions (6)]], and [[Fondaparinux clinical studies|Clinical Studies (14)]].]
| |
| | |
| ===Deep Vein Thrombosis Prophylaxis Following Abdominal Surgery===
| |
| In patients undergoing abdominal surgery, the recommended dose of ARIXTRA is 2.5 mg administered by subcutaneous injection once daily after [[hemostasis ]]has been established. Administer the initial dose no earlier than 6 to 8 hours after surgery. Administration of ARIXTRA earlier than 6 hours after surgery increases the risk of major bleeding. The usual duration of administration is 5 to 9 days, and up to 10 days of ARIXTRA was administered in clinical trials.
| |
| | |
| ===Deep Vein Thrombosis and Pulmonary Embolism Treatment===
| |
| In patients with acute symptomatic DVT and in patients with acute symptomatic PE, the recommended dose of ARIXTRA is 5 mg (body weight <50 kg), 7.5 mg (body weight 50 to 100 kg), or 10 mg (body weight >100 kg) by subcutaneous injection once daily (ARIXTRA treatment regimen). Initiate concomitant treatment with [[warfarin ]]sodium as soon as possible, usually within 72 hours. Continue treatment with ARIXTRA for at least 5 days and until a therapeutic oral anticoagulant effect is established (INR 2 to 3). The usual duration of administration of ARIXTRA is 5 to 9 days; up to 26 days of ARIXTRA injection was administered in clinical trials. [See [[Fondaparinux warnings and precautions |Warnings and Precautions (5.6)]], [[Fondaparinux adverse reactions|Adverse Reactions (6)]], and [[Fondaparinux clinical studies|Clinical Studies (14)]].]
| |
| | |
| ===Hepatic Impairment===
| |
| No dose adjustment is recommended in patients with mild to moderate hepatic impairment, based upon single-dose pharmacokinetic data. Pharmacokinetic data are not available for patients with severe hepatic impairment. Patients with hepatic impairment may be particularly vulnerable to bleeding during ARIXTRA therapy. Observe these patients closely for signs and symptoms of bleeding. [See [[Fondaparinux clinical pharmacology|Clinical Pharmacology (12.4)]].]
| |
| | |
| ===Instructions for Use===
| |
| ARIXTRA Injection is provided in a single-dose, prefilled syringe affixed with an automatic needle protection system. ARIXTRA is administered by subcutaneous injection. It must not be administered by intramuscular injection. ARIXTRA is intended for use under a physician’s guidance. Patients may self-inject only if their physician determines that it is appropriate and the patients are trained in subcutaneous injection techniques.
| |
| | |
| Prior to administration, visually inspect ARIXTRA to ensure the solution is clear and free of particulate matter.
| |
| | |
| To avoid the loss of drug when using the prefilled syringe, do not expel the air bubble from the syringe before the injection.Administration should be made in the fatty tissue, alternating injection sites (e.g., between the left and right anterolateral or the left and right posterolateral abdominal wall).
| |
| | |
| ===To administer ARIXTRA:===
| |
| | |
| [[image:fonda2.png]]
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARIXTRA (FONDAPARINUX SODIUM) INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=05bb2dd4-5fb5-4ec9-29a8-d200e62d1a8f | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| [[Category:Cardiovascular Drugs]] | |
| [[Category:Drugs]] | |